Aaron Sato

Aaron Sato is an accomplished executive with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as Chief Strategy Officer at Adimab since October 2024, Sato guides marketing strategies and engages with partners in various therapeutic areas, focusing on monoclonal and multispecific antibody discovery, T-cell engagers, and other technologies. As Chief Executive Officer of Spin Therapeutics since 2016, Sato leads a virtual company dedicated to developing novel serine proteinase inhibitors for rare diseases. Previous roles include General Manager at Twist Bioscience, where Sato provided end-to-end antibody solutions, and Chief Scientific Officer at multiple companies including LakePharma and Surrozen, focusing on research and protein engineering. Sato's educational background includes a PhD in Biological Chemistry from the Massachusetts Institute of Technology and a BS in Chemistry from the University of Puget Sound.